Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies

Cancer statistics, 2016

Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2016 · 16.2K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

Carcinoma of the Ovary

APM Heintz, Franco Odicino, Patrick Maisonneuve et al. · International Journal of Gynecology & Obstetrics · 2006 · 1.3K citations

Medicine, Gynecology, Oncology +10

Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia

Agustin A. García, Hal W. Hirte, Gini F. Fleming et al. · Journal of Clinical Oncology · 2007 · 549 citations

Medicine, Oncology, Pharmacology +16

Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer

Claire L. Cole, S. Lau, Alison Backen et al. · Cancer Biology & Therapy · 2010 · 93 citations · Full text

Medicine, Cancer Biology, Oncology +17

Screening Novel, Potent Multidrug-Resistant Modulators From Imidazole Derivatives

Liming Chen, Xing-Ping Wu, Ji-wu Ruan et al. · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · 2004 · 51 citations · Full text

Medicine, Oncology, Pharmacology +15